New drug combo aims to tame cirrhosis complications

NCT ID NCT06269484

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a combination of two drugs, zibotentan and dapagliflozin, is safe for people with cirrhosis, a serious liver condition. 73 adults with cirrhosis took part, receiving either the drug combo, zibotentan alone, or a placebo. The main goal was to check for side effects like fluid retention, which can worsen cirrhosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zibotentan and dapagliflozin
What this could lead to: If successful, this could point toward a safer treatment option for cirrhosis, potentially reducing fluid buildup and complications.
What could go wrong: This is an early Phase 2 safety study with only 73 participants, so results may not apply to all patients. The drugs may cause side effects like fluid retention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER CIRRHOSIS

Contacts and locations

Locations

Research Site

Englewood, Colorado, 80113, United States
Research Site

Charleston, South Carolina, 29425, United States
Research Site

San Antonio, Texas, 78215, United States
Research Site

Adelaide, 5000, Australia
Research Site

Kogarah, 2217, Australia
Research Site

Mitcham, 3132, Australia
Research Site

Mechelen, 2800, Belgium
Research Site

Liberec, 460 63, Czechia
Research Site

Mladá Boleslav, 293 01, Czechia
Research Site

Prague, 140 21, Czechia
Research Site

Leipzig, 04103, Germany
Research Site

Tübingen, 72076, Germany
Research Site

Milan, 20122, Italy
Research Site

Padova, 35128, Italy
Research Site

Roma, 00168, Italy
Research Site

Gifu, 500-8513, Japan
Research Site

Kawasaki-shi, 215-0026, Japan
Research Site

Kitakyusyu-shi, 806-8501, Japan
Research Site

Nagaoka-shi, 940-2085, Japan
Research Site

Niigata, 951-8520, Japan
Research Site

Sapporo, 006-8555, Japan
Research Site

Yokohama, 236-0004, Japan
Research Site

Bydgoszcz, 85-794, Poland
Research Site

Katowice, 40-081, Poland
Research Site

Mysłowice, 41-400, Poland
Research Site

Poznan, 61-848, Poland
Research Site

Bratislava, 83104, Slovakia
Research Site

Nitra, 950 01, Slovakia
Research Site

Trnava, 91702, Slovakia
Research Site

Aberdeen, AB25 2ZN, United Kingdom
Research Site

Hull, HU3 2KZ, United Kingdom
Research Site

Ipswich, IP4 5PD, United Kingdom
Research Site

London, SE5 9RS, United Kingdom
Research Site

Nottingham, NG7 2UH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.